CNS PHARMACEUTICALS AG

76 articles with CNS PHARMACEUTICALS AG

• CNS Pharmaceuticals Announces Inclusion in the Russell 2000® Index

  6/17/2021

  CNS Pharmaceuticals, Inc. today announced that it is to be added to the Russell 2000® Index effective June 25, 2021, after the close of the U.S. equity markets.

• CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

  5/19/2021

  Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study

• CNS Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Outlook

  5/14/2021

  CNS Pharmaceuticals, Inc., a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, reported its financial results for the quarter ended March 31, 2021.

• CNS Pharmaceuticals to Present at the Q2 Virtual Investor Summit

  5/11/2021

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system

• CNS Pharmaceuticals to Participate in Inaugural Emerging Growth Virtual Conference

  3/15/2021

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco, CEO

• CNS Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

  3/4/2021

  CNS Pharmaceuticals, Inc. announced that John Climaco, CEO of CNS Pharmaceuticals will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021.

• CNS Pharmaceuticals Berubicin Trial is On Schedule to Commence in March 2021

  2/25/2021

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today indicated that the clinical program for Berubicin is on track to start enrolling patients in March 2021

• CNS Pharmaceuticals to Present at the H.C. Wainwright BioConnect 2021 Conference

  1/7/2021

    CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)  ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that John Climaco , CEO of CNS Pharmaceuticals, will present at the virtual H.C. Wainwright BioC

• CNS Pharmaceuticals Announced Pricing of $10.0 Million Public Offering

  12/23/2020

   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced the pricing of an underwritten public offering of 5,000,000 shares of common stock and warrants to p

• CNS Pharmaceuticals Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin Today at 8:30am ET

  12/18/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, will host a conference call and live webcast today at 8:30am ET to discuss its Investigational New Drug (IND) approval for its lead product candidate, Berubicin,

• CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

  12/17/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Investigational New Drug (IND) application for its lead product candidate, Berubicin,

• CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy

  11/24/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points.

• CNS Pharmaceuticals and WPD Pharmaceuticals to Contribute Sponsorship to 2020 SNO Virtual Meeting

  11/19/2020

  CNS Pharmaceuticals, Inc.   (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced its joint sponsorship with WPD Pharmaceuticals for the 2020 Society of NeuroOncology (SNO) Vir

• CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin

  11/17/2020

  CNS Pharmaceuticals, Inc.   (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced

• CNS Pharmaceuticals to Discuss Phase 2 Clinical Trial Design to be Submitted for FDA Review in Webcast at 4:30 PM ET Today

  11/12/2020

  The discussion will be moderated by Robert LeBoyer, Managing Director of Equity Research at Ladenburg Thalmann & Co., Inc.

• CNS Pharmaceuticals Announces Adaptive Trial Design For Berubicin Phase 2 Clinical Trial To Be Submitted for FDA Review

  11/9/2020

  CNS to Discuss Potentially Pivotal Phase 2 Trial for Berubicin in Webcast on November 12th; Adaptive Trial Design May Open Opportunity for Expedited Pathway for Development and/or Approval

• CNS Pharmaceuticals Completes Manufacturing of Berubicin for Phase 2 Clinical Trial

  10/29/2020

  CNS' lead drug candidate Berubicin is proposed for the treatment of glioblastoma multiforme ("GBM"), an aggressive form of brain cancer

• CNS Pharmaceuticals Completes U.S. Manufacturing of Berubicin for Phase 2 Clinical Trial

  10/20/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced that the Company's U.S. manufacturer, Pharmaceutics International, Inc. ("Pii"), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme

• CNS Pharmaceuticals Highlights New Balancing Act Segment on Glioblastoma Airing on Lifetime TV

  10/12/2020

   CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today highlighted a new segment of "Behind the Mystery" focused on glioblastoma from The Balancing Act airing on Li

• CNS Pharmaceuticals Begins Manufacturing of Berubicin in Europe

  10/9/2020

  CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), today announced that the Company's European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"),